Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments CEO Andrew Toy reported an automatic share withholding to cover taxes tied to vesting stock units. On January 15, 2026, 60,764 shares of Class A common stock were withheld at $2.81 per share in connection with the vesting of 6.25% of a restricted stock unit (RSU) grant originally awarded on October 15, 2024.
Following this tax withholding, Toy directly beneficially owned 9,508,725 Class A shares. The remaining RSUs from the October 2024 grant are scheduled to vest quarterly in equal 6.25% installments, with the final vesting date on October 15, 2028, contingent on Toy’s continued service with the company.
Clover Health Investments (CLOV) filed a Form 4 detailing an automatic tax withholding transaction for its General Counsel & Secretary, Karen M. Soares. On January 15, 2026, 11,686 shares of Class A common stock were withheld at $2.81 per share to cover tax obligations arising from the vesting of restricted stock units (RSUs). After this withholding, Soares beneficially owned 1,210,679 shares of Class A common stock in direct ownership form.
The footnote explains that this withholding relates to the vesting of 6.25% of an RSU grant awarded on October 15, 2024. The remaining RSUs from this grant are scheduled to vest quarterly in equal 6.25% installments, with the final vesting date on October 15, 2028, assuming Soares continues in service through each vesting date.
Clover Health Investments, Corp. CEO Conrad Wai reported an automatic share withholding related to restricted stock vesting. On January 15, 2026, 25,868 shares of Class A common stock were withheld at $2.81 per share to cover tax obligations arising from the vesting of 6.25% of a prior RSU grant made on October 15, 2024.
After this tax withholding, Wai beneficially owned 1,025,806 Class A shares directly. In addition, a trust for the benefit of his family, of which he is a co‑trustee, held 1,610,482 Class A shares indirectly. The remaining RSUs from the 2024 grant are scheduled to vest quarterly in equal 6.25% installments through October 15, 2028, subject to his continued service.
Clover Health Investments, Corp. reported insider transactions by CEO, Medicare Advantage Jamie L. Reynoso in Class A Common Stock. On January 15, 2026, 14,732 shares were automatically withheld at
On January 20, 2026, Reynoso sold 4,597 shares at a weighted average price of
Clover Health Investments executive Brady Patrick Priest, CEO of Home Care, reported routine share withholding to cover taxes on vested RSUs. On January 15, 2026, 18,076 shares of Class A common stock at $2.81 per share were automatically withheld to satisfy tax obligations tied to the vesting of 6.25% of RSUs granted on October 15, 2024, leaving 2,210,507 shares beneficially owned directly. On January 18, 2026, an additional 36,923 shares at $2.54 per share were withheld for taxes on another 6.25% RSU vesting from a July 18, 2022 grant, after which Priest directly beneficially owned 2,173,584 shares of Class A common stock.
Clover Health (CLOV) insider Jamie Reynoso has filed a notice to sell common stock under Rule 144. The notice covers 4,597 common shares to be sold through Morgan Stanley Smith Barney LLC on or around 01/20/2026 on the NASDAQ market, with an indicated aggregate market value of
The notice also lists prior sales of Clover Health common stock for the same account during the past three months, including 2,102 shares sold on 01/07/2026 for gross proceeds of
Clover Health Investments, Corp. reported that CEO Andrew Toy will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2026, with a live webcast available through the company’s investor relations website. The slide deck for this event is furnished as an exhibit.
The company also issued a press release on January 14, 2026 announcing preliminary Medicare Advantage Annual Election Period results, which is likewise furnished as an exhibit. The accompanying materials include forward-looking statements discussing expected 2026 GAAP net income profitability, the impact of a 4.0 Stars rating for Clover’s PPO Medicare Advantage plans for payment year 2026, its 2026 financial outlook, membership growth and retention, Clover Assistant usage and investment, CMS’ 2026 rate update, Part D direct subsidies, and cost efficiency initiatives, all subject to significant risks and uncertainties.
Clover Health Investments director and 10% owner Vivek Garipalli reported a large RSU vesting and related share movements. On January 7, 2026, the final 20% of a restricted stock unit grant from January 7, 2021 vested. This delivered 1,686,750 shares of Class B common stock and triggered the automatic conversion of 1,655,949 Class B shares into the same number of Class A shares, which were withheld by the company to satisfy tax obligations at a value of $2.59 per share.
Following these transactions, Garipalli directly held 1,856,247 shares of Class A common stock and 8,591,093 shares of Class B common stock75,694,143 shares of Class B common stock through NJ Healthcare Investments, LLC and 11,500,000 shares of Class B common stock through Caesar Clover, LLC, with each Class B share convertible into one Class A share.
Clover Health Investments, Corp. reported that director Demetrios L. Kouzoukas received an equity award in the form of restricted stock units. On January 6, 2026, he acquired 79,365 shares of Class A common stock at a price of $0 per share, reflecting the grant of time-based RSUs rather than a cash purchase.
These RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that vesting date. After this grant, Kouzoukas beneficially owned 605,980 shares of Class A common stock, held directly.
Clover Health Investments, Corp. director reports stock-based award. Director Carladenise Armbrister Edwards received 79,365 shares of Class A Common Stock on January 6, 2026, as part of a time-based restricted stock unit (RSU) grant at a price of $0 per share. These RSUs represent stock that will vest in full on the first anniversary of January 6, 2026, if she continues serving as a director through that date. Following this grant, she beneficially owns 352,592 shares of Class A Common Stock in total, reported as directly held.
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
